Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAnpario Regulatory News (ANP)

Share Price Information for Anpario (ANP)

Share Price is delayed by 15 minutes
Get Live Data
520.00    5.00 (0.97%)
Bid:
510.00
Ask:
530.00
Spread: 20.00 (3.922%)
Market Cap: £85.47m
ANP Live PriceLast checked at - London Stock Exchange

Intraday Anpario Share Chart

Trading Statement

3 Feb 2014 07:00

3 February 2014

Anpario plc

(“the Company” or “Anpario”)

Pre Close Trading Statement

Anpario, the international producer of natural feed additives for animal health, hygiene and nutrition, is pleased to release a Pre Close Trading Statement.

The Company expects to deliver results for the year ended 31December 2013 in line with market expectations. The results will be announced in early April 2014.

Anpario has delivered strong sales growth from all its international brands and this advance reflects the Company’s investment in expanding its sales and technical resources at its regional offices in Brazil, China and Malaysia.

The growing interest from potential customers in North America has encouraged the Company to establish a subsidiary in the United States. This new, wholly owned, subsidiary is based in South Carolina and includes sales, warehousing and distribution facilities to enable it to offer Anpario’s products throughout North America.

The United States operation complements subsidiaries already formed in Brazil and China and means the Company is now firmly located in the world’s three principal pig and poultry producing countries. These businesses serve territories which in total account for over half the world’s output of pigs and poultry and will provide a strong platform for future growth.

The balance sheet remains strong and debt free with cash balances of £4.8m at the year end.

The Company is greatly encouraged by the number of new opportunities opening up in existing and new markets as customers become increasingly aware of the performance enhancing value of Anpario’s product portfolio. Customers recognise the benefit of Anpario’s natural products that are increasingly replacing the traditional use of antibiotics. The Company’s investment in developing its product ranges backed by experienced sales teams has placed it in a strong position to maintain its growth record.

Anpario plc
David Bullen, Chief Executive Officer +44 (0)791 955 2040
Karen Prior, Group Finance Director +44 (0)1909 537 380
FinnCap
Matthew Robinson / Henrik Persson - Corporate Finance
Stephen Norcross - Corporate Broking +44 (0)20 7600 1658

Copyright Business Wire 2014

Date   Source Headline
18th Jun 20267:00 amRNSAGM Statement
11th Jun 20267:00 amRNSTransaction in Own Shares and Total Voting Rights
10th Jun 20267:00 amRNSTransaction in Own Shares and Total Voting Rights
9th Jun 20267:00 amRNSTransaction in Own Shares and Total Voting Rights
3rd Jun 20267:00 amRNSTransaction in Own Shares and Total Voting Rights
2nd Jun 20267:00 amRNSTransaction in Own Shares and Total Voting Rights
28th May 20267:00 amRNSPosting of Annual Report and Notice of AGM
20th May 20267:00 amRNSTransaction in Own Shares and Total Voting Rights
19th May 20267:00 amRNSTransaction in Own Shares and Total Voting Rights
18th May 20267:00 amRNSTransaction in Own Shares and Total Voting Rights
15th May 20267:00 amRNSTransaction in Own Shares and Total Voting Rights
14th May 20267:00 amRNSTransaction in Own Shares and Total Voting Rights
13th May 20267:00 amRNSTransaction in Own Shares and Total Voting Rights
12th May 20267:00 amRNSTransaction in Own Shares and Total Voting Rights
11th May 20267:00 amRNSTransaction in Own Shares and Total Voting Rights
8th May 20267:00 amRNSTransaction in Own Shares and Total Voting Rights
7th May 20267:00 amRNSTransaction in Own Shares and Total Voting Rights
6th May 20267:00 amRNSTransaction in Own Shares and Total Voting Rights
5th May 20267:00 amRNSTransaction in Own Shares and Total Voting Rights
1st May 20267:00 amRNSTransaction in Own Shares and Total Voting Rights
30th Apr 20267:00 amRNSTransaction in Own Shares and Total Voting Rights
29th Apr 20267:00 amRNSTransaction in Own Shares and Total Voting Rights
28th Apr 20267:00 amRNSTransaction in Own Shares and Total Voting Rights
27th Apr 20267:00 amRNSLaunch of Share Buyback Programme
10th Apr 202612:00 pmRNSInvestor Presentation via Investor Meet Company
31st Mar 20267:00 amRNSFinal Results
3rd Mar 20267:00 amRNSHolding(s) in Company
19th Jan 20263:44 pmRNSBlock listing return
19th Jan 20267:00 amRNSFull year trading statement
23rd Sep 20257:00 amRNSChange of Auditor
10th Sep 20257:00 amRNSInterim Results
9th Sep 202511:36 amRNSInvestor Presentation via Investor Meet Company
22nd Jul 20257:00 amRNSJSOP Awards and TVR
17th Jul 20251:15 pmRNSBlock listing return
19th Jun 20252:01 pmRNSResult of AGM
19th Jun 20257:00 amRNSAGM Statement
19th May 20255:33 pmRNSPosting of Annual Report and Notice of AGM
2nd May 20257:00 amRNSInvestor Presentation via Investor Meet Company
8th Apr 20257:00 amRNSTransaction in Own Shares
7th Apr 20257:00 amRNSLaunch of Share Buyback Programme
2nd Apr 20257:00 amRNSAward Exercise, Voting Rights & Director Dealing
31st Mar 20257:00 amRNSFinal Results
26th Mar 20257:00 amRNSUpdate on Timing of Full Year Results Announcement
15th Jan 20257:00 amRNSGrant of options under SAYE Scheme
10th Jan 20257:00 amRNSFull year trading statement
9th Jan 20257:00 amRNSTotal Voting Rights
16th Dec 20247:00 amRNSExercise of Options and Director/PDMR Shareholding
16th Dec 20247:00 amRNSLaunch of SAYE Scheme
29th Nov 20247:00 amRNSTotal Voting Rights
30th Sep 20247:00 amRNSAcquisition of Bio-Vet Inc.

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.